GRAL Shareholder Alert: August 4, 2026 Lead Plaintiff Deadline in GRAIL, Inc. Securities Class Action - Contact The Gross Law Firm

Shareholders who purchased shares of GRAIL, Inc. (NASDAQ: GRAL) during the class period of May 13, 2025 to February 19, 2026 are encouraged to contact The Gross Law Firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.

According to the complaint, defendants provided overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of GRAIL’s NHS-Galleri trial following the reveal of the top-line results covering the first screening round. Notably, as defendants have since attested, the trial as executed within the three-year follow-up period was insufficient to demonstrate the achievability of a reduction in Stage III-IV cancers; defendants disclosed the trial period, and thus the screening duration, was apparently insufficient to demonstrate whether the primary endpoint was achievable.

Defendants further repeatedly refused to provide detailed topline results or other data from the NHS-Galleri study, potentially concealing known trendlines which arguably suggested either a longer timeline would be necessary or otherwise that the probability of achieving the statistical reduction in Stage III & IV cancers by the trial’s end had been reduced.

On February 19, 2026, GRAIL announced that the “primary endpoint of statistically significant Stage III-IV reduction was not observed” in the NHS-Galleri Trial. The Company attributed this shortcoming, in part, on “probably need[ing] a longer follow-up time to be able to [compare the study arms] adequately.” Following this news, the price of GRAIL’s common stock declined dramatically. From a closing market price of $101.53 per share on February 19, 2026, Grail’s stock price fell to $50.21 per share on February 20, 2026, a decline of about 50.55% in the span of just a single day.

The deadline to seek to be a lead plaintiff is August 4, 2026. Shareholders should not delay in registering for this class action. Once registered, shareholders will be enrolled in a portfolio monitoring software to provide status updates throughout the lifecycle of the case. There is no cost or obligation to participate.